Boston Scientific (NYSE:BSX) Director David Habiger Acquires 2,200 Shares

Boston Scientific Corporation (NYSE:BSX) Director David Habiger acquired 2,200 shares of Boston Scientific stock in a transaction dated Tuesday, May 19th. The shares were bought at an average cost of $56.95 per share, for a total transaction of $125,290.00. Following the completion of the purchase, the director directly owned 11,628 shares of the company’s stock, valued at approximately $662,214.60. The trade was a 23.33% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Boston Scientific Stock Up 0.7%

NYSE BSX opened at $57.08 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $84.84 billion, a PE ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 1 year low of $52.52 and a 1 year high of $109.50. The business’s 50-day moving average is $62.21 and its 200 day moving average is $80.40.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BSX. UBS Group decreased their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. JPMorgan Chase & Co. decreased their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Finally, Citigroup cut their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp increased its position in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares during the period. Capital World Investors increased its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Finally, Morgan Stanley increased its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Heavy insider buying is often seen as a vote of confidence from management and can boost investor sentiment. Article Title
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the FRACTURE trial meeting all primary safety and effectiveness endpoints. That strengthens the case for future regulatory approval and supports the company’s growth story. Article Title
• Neutral Sentiment: Baird kept an Outperform rating on BSX but trimmed its price target to $75 from $78, suggesting Wall Street still likes the name even as expectations are being adjusted. Article Title
• Negative Sentiment: Some recent commentary said Boston Scientific fell due to weak results, which may be weighing on sentiment and reminding investors that the stock has faced pressure despite longer-term growth prospects. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.